ONTARGET^® Trial Results Webcast

Wednesday 2nd April 2008

ONTARGET^® Trial Results Webcast

American College of Cardiology (ACC) Annual Meeting

ONTARGET^® (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) is the largest outcomes-led cardiovascular trial undertaken with an angiotensin II receptor blocker (ARB) and has the broadest population ever included in a study of this type. It has been collecting data on cardio and vascular protection in a clinical setting for over five years and now the results are here.

Lead investigator Professor Salim Yusuf exclusively presents the results of The ONTARGET^® Trial and provides his interpretation of the outcomes from the American College of Cardiology (ACC) annual meeting in Chicago. Listen in as Professor Yusuf and other medical experts discuss the potential implications of the outcomes for clinical practice and bring the ONTARGET^® results straight to your desktop.

• Click here to view exclusive webcast

This webcast follow the presentations held on occasion of the American College of Cardiology (ACC) Annual Meeting 2008 between 29th March - 3rd April 2008. It is reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited